David Rand, MD
Ophthalmology · Pompano Beach, FLNPI 1548491491
Payments from drug & device makers
What this record shows
12 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 55.6% of the total. Reporting peaked in 2019 at $237 and has fallen 56.2% since, to $104 in 2025. That places this record below the midpoint for ophthalmology clinicians in FL, where the typical reported total is $1,824.
Across 23 payments — averaging $30.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$386
- Genentech, Inc.$61
- Johnson & Johnson Surgical Vision, Inc.$58
- Eyevance Pharmaceuticals LLC$34
- AbbVie$29
- Bausch & Lomb Americas Inc.$24
- plus $103 from 6 others
Across 5 payments — averaging $13,466 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$67K
What the payments were for
- Food & beverage$41159%
- Education$28441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 8 | $386 |
| Genentech, Inc. | 1 | $61 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $58 |
| Eyevance Pharmaceuticals LLC | 2 | $34 |
| AbbVie(2 entities) | 2 | $29 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
| Aerie Pharmaceuticals, Inc. | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Novartis | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Ocular Therapeutix, Inc. | 1 | $16 |
| Alcon Research LLC | 1 | $12 |
How this compares
$695 in reported general payments places this provider in the 30th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 50 | $22,013 |
| LumiganBimatoprost | 53 | $21,120 |
| CombiganBrimonidine Tartrate/Timolol | 53 | $17,022 |
| RestasisCyclosporine | 26 | $15,955 |
| VyzultaLatanoprostene Bunod | 19 | $13,914 |
| Prednisolone Acetate | 437 | $13,676 |
| Cyclosporine | 17 | $8,146 |
| Alphagan PBrimonidine Tartrate | 13 | $6,662 |
| Latanoprost | 792 | $5,865 |
| Ketorolac Tromethamine | 271 | $5,729 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 30 | $4,659 |
| XiidraLifitegrast | 11 | $4,407 |
| Brimonidine Tartrate | 407 | $4,404 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 259 | $3,594 |
| Ofloxacin | 325 | $3,543 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $29 | $60,759145 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $22 | $22,01350 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $24 | $18,32130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Pompano Beach
- Carl DanzigPompano Beach$484K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.